SRX246
Sponsors
Azevan Pharmaceuticals
Conditions
Aggressive Behavior in Fragile X SyndomeAnxietyFearHealthyHuntington's DiseaseIntermittent Explosive DisorderIrritable MoodPTSD
Phase 1
Study of SRX246 Capsules in Healthy Adult Volunteers
CompletedNCT00910455
Start: 2009-05-31End: 2009-09-30Updated: 2010-03-17
Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers
CompletedNCT01088932
Start: 2010-03-31End: 2010-07-31Updated: 2010-07-20
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
CompletedNCT02055638
Start: 2014-05-31End: 2016-05-31Updated: 2023-07-21
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
NCT02922166
Start: 2017-02-03End: 2019-12-31Updated: 2019-06-10
Phase 2
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
CompletedNCT02507284
Start: 2016-05-10End: 2018-12-21Updated: 2023-07-20
Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
TerminatedNCT02733614
Start: 2016-12-31End: 2021-03-31Updated: 2021-11-01
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
Not yet recruitingNCT07328529
Start: 2026-03-31End: 2028-03-31Target: 80Updated: 2026-01-09